1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

EcoR1 Capital, LLC Buys CytomX Therapeutics Inc, Cascadian Therapeutics Inc, Fate Therapeutics Inc, Sells Alexion Pharmaceuticals Inc, Ardelyx Inc, Five Prime Therapeutics Inc

San Francisco, CA, based Investment company EcoR1 Capital, LLC buys CytomX Therapeutics Inc, Cascadian Therapeutics Inc, Fate Therapeutics Inc, Aclaris Therapeutics Inc, OvaScience Inc, Jounce Therapeutics Inc, aTyr Pharma Inc, Atara Biotherapeutics Inc, Regulus Therapeutics Inc, Versartis Inc, sells Alexion Pharmaceuticals Inc, Ardelyx Inc, Five Prime Therapeutics Inc, FibroGen Inc, Editas Medicine Inc during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, EcoR1 Capital, LLC. As of 2017-03-31, EcoR1 Capital, LLC owns 30 stocks with a total value of $340 million. These are the details of the buys and sells.

For the details of EcoR1 Capital, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=EcoR1+Capital%2C+LLC

These are the top 5 holdings of EcoR1 Capital, LLC
  1. Assembly Biosciences Inc (ASMB) - 2,943,164 shares, 22.08% of the total portfolio.
  2. Ironwood Pharmaceuticals Inc (IRWD) - 2,905,515 shares, 14.59% of the total portfolio. Shares added by 1.75%
  3. Galapagos NV (GLPG) - 551,041 shares, 13.98% of the total portfolio. Shares reduced by 1.83%
  4. Ascendis Pharma A/S (ASND) - 1,025,700 shares, 8.45% of the total portfolio. Shares added by 5.12%
  5. Kura Oncology Inc (KURA) - 2,611,906 shares, 6.77% of the total portfolio.
New Purchase: CytomX Therapeutics Inc (CTMX)

EcoR1 Capital, LLC initiated holdings in CytomX Therapeutics Inc. The purchase prices were between $10.71 and $18.89, with an estimated average price of $13.16. The stock is now traded at around $14.71. The impact to the portfolio due to this purchase was 4.04%. The holdings were 794,969 shares as of 2017-03-31.

New Purchase: Cascadian Therapeutics Inc (CASC)

EcoR1 Capital, LLC initiated holdings in Cascadian Therapeutics Inc. The purchase prices were between $3.64 and $5.1, with an estimated average price of $4.2. The stock is now traded at around $4.75. The impact to the portfolio due to this purchase was 3.66%. The holdings were 3,000,000 shares as of 2017-03-31.

New Purchase: Fate Therapeutics Inc (FATE)

EcoR1 Capital, LLC initiated holdings in Fate Therapeutics Inc. The purchase prices were between $2.69 and $5.05, with an estimated average price of $3.66. The stock is now traded at around $3.99. The impact to the portfolio due to this purchase was 3.4%. The holdings were 2,537,026 shares as of 2017-03-31.

New Purchase: OvaScience Inc (OVAS)

EcoR1 Capital, LLC initiated holdings in OvaScience Inc. The purchase prices were between $1.37 and $1.96, with an estimated average price of $1.59. The stock is now traded at around $1.32. The impact to the portfolio due to this purchase was 1.93%. The holdings were 3,512,332 shares as of 2017-03-31.

New Purchase: Jounce Therapeutics Inc (JNCE)

EcoR1 Capital, LLC initiated holdings in Jounce Therapeutics Inc. The purchase prices were between $16.58 and $25.58, with an estimated average price of $21.19. The stock is now traded at around $23.05. The impact to the portfolio due to this purchase was 1.67%. The holdings were 258,457 shares as of 2017-03-31.

New Purchase: Regulus Therapeutics Inc (RGLS)

EcoR1 Capital, LLC initiated holdings in Regulus Therapeutics Inc. The purchase prices were between $1.05 and $2.55, with an estimated average price of $1.59. The stock is now traded at around $1.43. The impact to the portfolio due to this purchase was 0.73%. The holdings were 1,510,000 shares as of 2017-03-31.

Added: Aclaris Therapeutics Inc (ACRS)

EcoR1 Capital, LLC added to the holdings in Aclaris Therapeutics Inc by 62.58%. The purchase prices were between $25.1 and $32.65, with an estimated average price of $28.83. The stock is now traded at around $25.67. The impact to the portfolio due to this purchase was 2.27%. The holdings were 673,100 shares as of 2017-03-31.

Added: aTyr Pharma Inc (LIFE)

EcoR1 Capital, LLC added to the holdings in aTyr Pharma Inc by 134.67%. The purchase prices were between $2.35 and $4, with an estimated average price of $3.27. The stock is now traded at around $3.40. The impact to the portfolio due to this purchase was 1.35%. The holdings were 2,292,659 shares as of 2017-03-31.

Added: Atara Biotherapeutics Inc (ATRA)

EcoR1 Capital, LLC added to the holdings in Atara Biotherapeutics Inc by 101.48%. The purchase prices were between $12.65 and $22.7, with an estimated average price of $16.56. The stock is now traded at around $15.43. The impact to the portfolio due to this purchase was 1.32%. The holdings were 434,812 shares as of 2017-03-31.

Added: Bristol-Myers Squibb Company (BMY)

EcoR1 Capital, LLC added to the holdings in Bristol-Myers Squibb Company by 99.30%. The purchase prices were between $46.82 and $60.13, with an estimated average price of $54.85. The stock is now traded at around $54.09. The impact to the portfolio due to this purchase was 0.13%. The holdings were 17,060 shares as of 2017-03-31.

Sold Out: Alexion Pharmaceuticals Inc (ALXN)

EcoR1 Capital, LLC sold out the holdings in Alexion Pharmaceuticals Inc. The sale prices were between $118.53 and $144.77, with an estimated average price of $128.92.

Sold Out: Ardelyx Inc (ARDX)

EcoR1 Capital, LLC sold out the holdings in Ardelyx Inc. The sale prices were between $11 and $14.95, with an estimated average price of $13.16.

Sold Out: Five Prime Therapeutics Inc (FPRX)

EcoR1 Capital, LLC sold out the holdings in Five Prime Therapeutics Inc. The sale prices were between $34.89 and $52.15, with an estimated average price of $44.08.

Sold Out: Editas Medicine Inc (EDIT)

EcoR1 Capital, LLC sold out the holdings in Editas Medicine Inc. The sale prices were between $17.04 and $27.27, with an estimated average price of $20.72.

Sold Out: Chimerix Inc (CMRX)

EcoR1 Capital, LLC sold out the holdings in Chimerix Inc. The sale prices were between $4.54 and $6.49, with an estimated average price of $5.67.

Sold Out: Egalet Corp (EGLT)

EcoR1 Capital, LLC sold out the holdings in Egalet Corp. The sale prices were between $4.45 and $8.38, with an estimated average price of $5.21.

Reduced: FibroGen Inc (FGEN)

EcoR1 Capital, LLC reduced to the holdings in FibroGen Inc by 93.88%. The sale prices were between $21.3 and $26.45, with an estimated average price of $24.36. The stock is now traded at around $27.44. The impact to the portfolio due to this sale was -4.38%. EcoR1 Capital, LLC still held 42,009 shares as of 2017-03-31.

Reduced: Xencor Inc (XNCR)

EcoR1 Capital, LLC reduced to the holdings in Xencor Inc by 37.38%. The sale prices were between $21.67 and $26.65, with an estimated average price of $24.1. The stock is now traded at around $21.85. The impact to the portfolio due to this sale was -1.17%. EcoR1 Capital, LLC still held 234,813 shares as of 2017-03-31.

Reduced: Syndax Pharmaceuticals Inc (SNDX)

EcoR1 Capital, LLC reduced to the holdings in Syndax Pharmaceuticals Inc by 87.11%. The sale prices were between $6.68 and $14.86, with an estimated average price of $10.38. The stock is now traded at around $14.11. The impact to the portfolio due to this sale was -0.55%. EcoR1 Capital, LLC still held 35,301 shares as of 2017-03-31.



Here is the complete portfolio of EcoR1 Capital, LLC. Also check out:

1. EcoR1 Capital, LLC's Undervalued Stocks
2. EcoR1 Capital, LLC's Top Growth Companies, and
3. EcoR1 Capital, LLC's High Yield stocks
4. Stocks that EcoR1 Capital, LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


GuruFocus has detected 1 Warning Sign with Aclaris Therapeutics Inc $ACRS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Performances of the stocks mentioned by insider


User Generated Screeners


HOLKLSUMini Group Low Shiller P/E
doonich5% within 52wk
JefulfordNegative EV
JefulfordP/graham <0.5
JefulfordP/TB <1
JefulfordP/TB <0.7
JefulfordNCAV <1
peterc123NCAV New
wwygeraSmall-Cap Growth
sidrkfgSmall Cap Growth
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK